top of page
Health News
The latest news on health and medicine, covid, vaccines, global health, mental health, Obamacare, health insurance, Medicare, Medicaid, opioids, cancer
A Degree in Health Science Could Be Just What the Doctor Ordered
A Degree in Health Science Could Be Just What the Doctor Ordered
QUANTUNG PHARMA
FDA Puts Clinical Hold on Hemogenyx’s CAR-T AML Therapy
The FDA has placed a clinical hold on Hemogenyx Pharmaceuticals’ investigational HEMO-CAR-T, which is being trialed for the treatment of acu
QUANTUNG PHARMA
Novavax Amends COVID-19 Contract with Canada, Snags $350M for Unused Shots
Amid declining demand for COVID-19 vaccines, embattled biotech Novavax is revising its advanced purchase contract with Canada’s department o
QUANTUNG PHARMA
BrainStorm Builds NurOwn’s Case in ALS with Biomarker Data
Friday, BrainStorm Cell Therapeutics posted positive Phase III data for its amyotrophic lateral sclerosis candidate NurOwn, showing that the
QUANTUNG PHARMA
CRISPR on the Cusp: The Promise and the Pain Points
angioedema patients treated with Intellia’s NTLA-2002—an in vivo CRISPR-Cas9 therapy— had an average 95% reduction in the sudden, debilitati
QUANTUNG PHARMA
BMS’ Sotyktu gets NICE green light for NHS use
The therapy becomes an option for moderate-to-severe plaque psoriasis in certain adults
QUANTUNG PHARMA
King’s College London and Pioneer Group in incubator link-up
Pioneer Group has announced a partnership with King’s College London to launch new dedicated start-up incubators in biotech and medtech on t
QUANTUNG PHARMA
J&J Extends Lifeline to Nanobiotix in Potential $1.8B Licensing Deal
Johnson & Johnson has capitalized on the shaky financial ground at French biotech Nanobiotix by licensing its lead product, NBTXR3, intended
QUANTUNG PHARMA
BeiGene Ups ADC Investment with $1.3B DualityBio Licensing Deal
Chinese biotech BeiGene has acquired an exclusive license of an investigational antibody-drug conjugate for $1.3 billion from Shanghai-based
QUANTUNG PHARMA
Edinburgh researchers and LifeArc to boost MND treatment processes
A project involving researchers based in Edinburgh wants to establish effective combinations of existing drugs which, used together, could t
QUANTUNG PHARMA
Digital Health London’s Accelerator programme selects Aide
Project aims to boost the adoption of technology across London’s NHS and help patients manage conditions
QUANTUNG PHARMA
Genfit and Ipsen announce elafibranor results
ELATIVE, a randomised PBC trial involving 161 patients, has successfully met its primary endpoint
QUANTUNG PHARMA
Teva reveals critical Ajovy data
Therapy has been developed to reduce the frequency, duration and severity of migraine attacks
QUANTUNG PHARMA
Momentum for Poolbeg and CytoReason’s AI collaboration
Partnership establishes several influenza therapy targets using artificial intelligence
QUANTUNG PHARMA
Novartis reveals five-year efficacy data for Kesimpta
Patients treated with Kesimpta experienced considerable decreases in relapse rates
QUANTUNG PHARMA
GeneCode receives record Parkinson’s funding
European Innovation Council Accelerator finances treatment development drive for condition
QUANTUNG PHARMA
Positive efficacy data for Sensorian’s candidate I QUANTUNG Pharma
SENS-401 has been developed for hearing preservation among adult patients following cochlear implantation
QUANTUNG PHARMA
Biotech firms target weight-loss drugs without Wegovy's side-effects
Biotech firms target weight-loss drugs without Wegovy's side-effects, QUNATUNG Pharma
QUANTUNG PHARMA
Incyte’s Opzelura gets MHRA authorisation
Incyte Biosciences has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for
QUANTUNG PHARMA
Vertex’s Orkambi receives EC approval I QUANTUNG Pharma
Orkambi is an oral treatment for very young children that combines both lumacaftor and ivacaftor
QUANTUNG PHARMA
bottom of page